Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.46 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | NMT1 | P30419 | 5/20 | 0.39 |
| ▸ | NMT2 | O60551 | 2/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27661085 | 0.84 | TLR7 (0.43) | TLR7MAOBCYP3A4NMT1 | |
| SCHEMBL3868134 | 0.84 | TLR7 (0.48) | TLR7 | |
| SCHEMBL29463868 | 0.82 | ACSS2 (0.46) | TLR7MAOBACSS2CYP3A4MEN1 | |
| SCHEMBL18638556 | 0.82 | ACSS2 (0.46) | TLR7MAOBACSS2CYP3A4MEN1 | |
| SCHEMBL1486435 | 0.82 | TLR7 (0.70) | TLR7ACSS2CYP3A4 | |
| SCHEMBL1486498 | 0.81 | LTA4H (0.47) | GRM4MEN1MAPTKMT2A | |
| SCHEMBL18638451 | 0.80 | ACSS2 (0.51) | TLR7MAOBACSS2CYP3A4DYRK1A | |
| SCHEMBL1486482 | 0.80 | MAOB (0.41) | TLR7GRM4MAOBACSS2CYP3A4 | |
| SCHEMBL9387631 | 0.79 | TLR7 (0.61) | TLR7MAPT | |
| Water SCHEMBL10743629 | 0.78 | TLR7 (0.60) | TLR7MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1658076-B1 | ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2013-03-06 | — | — | EP | disclosed |
| US-8263594-B2 | Aryloxy and arylalkyleneoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-09-11 | — | — | US | disclosed |
| US-20110144099-A1 | ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY | 2011-06-16 | — | — | US | disclosed |
| US-7897597-B2 | Aryloxy and arylalkyleneoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
| EP-1658076-A4 | ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2009-02-25 | — | — | EP | disclosed |
| US-20090018122-A1 | Aryloxy and Arylalkyleneoxy Substituted Imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2009-01-15 | — | — | US | disclosed |
| CN-1842336-A | Aryloxy and arylalkyleneoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES CO (US) | 2006-10-04 | — | — | CN | disclosed |
| EP-1658076-A1 | ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005020999-A1 | ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018122-A1 | Aryloxy and Arylalkyleneoxy Substituted Imidazoquinolines | IL2, IFNG, IRF3 | TLR7 45/4885GRM4 2290/4885MAOB 3487/4885 |
| US-20110144099-A1 | ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES | IL2, IFNG, IRF3 | TLR7 42/4885GRM4 1819/4885MAOB 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.